RxDoctor Payments Data

Angela Ewing, PA

Physician Assistant · Rome, GANPI 1801885942

Payments from drug & device makers

$2,075in general payments, 2019–2025

Across 122 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$270
  • MDD US Operations, LLC$213
  • AbbVie$208
  • Biogen$183
  • UCB, Inc.$176
  • Biohaven Pharmaceutical Holding Company Ltd.$132
  • plus $894 from 19 others

What the payments were for

  • Food & beverage$2,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,075 in reported general payments places this provider in the 75th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$35,047
Medicare patients
286
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$95,445
Aimovig AutoinjectorErenumab-Aooe89$75,290
UbrelvyUbrogepant58$72,973
Emgality PenGalcanezumab-Gnlm37$26,727
Nurtec OdtRimegepant Sulfate20$22,442
RytaryCarbidopa/Levodopa11$10,586
Levetiracetam140$4,843
Lacosamide38$4,495
Pregabalin155$2,850
Memantine Hcl122$2,529
Gabapentin206$2,482
Carbidopa-LevodopaCarbidopa/Levodopa62$2,131
Entacapone12$1,807
Rivastigmine17$1,641
Ropinirole ErRopinirole Hcl11$1,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$16$95,44513 claims
AbbVieUbrelvy$208$72,97358 claims
PfizerNurtec Odt$270$22,44220 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$26$12,02924 claims
Upsher-smith Laboratories LLCTopiramate$16$76251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →